Leading the Way in Life Science Technologies

GEN Exclusives

More »

New Products

More »
Aug 1, 2012 (Vol. 32, No. 14)

Binding Site

Click Image To Enlarge +

RF/IgG Absorbent Reagent

Specifically designed for use in conjunction with immunodiagnostic assays, the RF/IgG absorbent reagent is formulated to remove both IgG and RF-IgM molecules from human serum. The reagent can prevent these bodily components from nonspecific binding within the test sample. It can also enhance overall specificity by reducing both the number of false positive test results from native IgG components and the number of false negative test results from native RF-IgM components. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of operator-oriented packaging configurations including bulk-sized formats.

Specifically designed for use in conjunction with immunodiagnostic assays, the RF/IgG absorbent reagent is formulated to remove both IgG and RF-IgM molecules from human serum. The reagent can prevent these bodily components from nonspecific binding within the test sample. It can also enhance overall specificity by reducing both the number of false positive test results from native IgG components and the number of false negative test results from native RF-IgM components. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of operator-oriented packaging configurations including bulk-sized formaSpecifically designed for use in conjunction with immunodiagnostic assays, the RF/IgG absorbent reagent is formulated to remove both IgG and RF-IgM molecules from human serum. The reagent can prevent these bodily components from nonspecific binding within the test sample. It can also enhance overall specificity by reducing both the number of false positive test results from native IgG components and the number of false negative test results from native RF-IgM components. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of operator-oriented packaging configurations including bulk-sized formats.

 

  • Binding Site
  • 5889 Oberlin Drive #101
  • San Diego, CA, 92121
  • UNITED STATES

Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »